Inhibrx Biosciences, Inc. (INBX NASDAQ) stock market data APIs
$72.1082
0.14(0.2%)
as of October 30, 2026
Try our APIs with
free plan!
Inhibrx Biosciences, Inc. Financial Data Overview
Price chart is built with
Anychart
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California.
Prev. Close
72.1082
Open
72.2432
High
73.616
Low
66.2899
52 wk Range
57.3-155.29
Market Cap
1 056 M
Shares Outstanding
14 718 K
EPS
-2.34
Beta
3.822
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Inhibrx Biosciences, Inc. (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Inhibrx Biosciences, Inc. data using free add-ons & libraries
Get Inhibrx Biosciences, Inc. Fundamental Data
Inhibrx Biosciences, Inc. Fundamental data includes:
- Net Revenue:
- EBITDA: -125 604 000
- Earnings Per Share: -8
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get Inhibrx Biosciences, Inc. Earnings data
Corporate Events Calendar & News package for
$
19.99
/mo.
What’s included:
- Latest Release: 2026-08-13
- EPS/Forecast: -2.5
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Inhibrx Biosciences, Inc. News
New
Inhibrx’s Cancer Drug Nearly Doubled Response Rate, So Why Did the Stock Fall?
Inhibrx Biosciences, Inc. (NASDAQ:INBX) delivered the kind of clinical update that would normally be expected to get investors' attention. Its experimental cancer drug INBRX-106, combined with Merck's...
Inhibrx Founder and CEO Mark Lappe Buys 25,000 Shares for $2.6 Million. What Does His Confidence Tell Investors?
Mark Lappe, Chief Executive Officer, purchased 25,000 shares of Inhibrx Biosciences, Inc. (NASDAQ:INBX) on September 8, 2026. SEC Form 4 filing. Transaction summary Metric Value Shares purchased 25,...
6 Biotech Stocks That Delivered Stunning Gains: INBX +700%, PVLA +500%, MBX +300%, ABSI +200% & More
(RTTNews) - "The market is a device for transferring money from the impatient to the patient." - Warren Buffett. Successful investing often comes down to patience, conviction, and the ability to stay...
Inhibrx Biosciences (INBX) Announces Positive Interim Results From Phase 2 Portion of HexAgon Study
Inhibrx Biosciences, Inc. (NASDAQ:INBX) is one of the best small cap stocks to buy for 10x potential. Inhibrx Biosciences, Inc. (NASDAQ:INBX) announced on May 11 positive interim results from the rand...
Get Inhibrx Biosciences, Inc. fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.